New 36-Month Apitegromab Extension Data Reinforce Long-Term

New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy

New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Florida , United States , Orlando , Rushmie Nofsinger , Teagan White , Disney Swan , Thomas Crawford , Jay Backstrom , Thomaso Crawford , Research Clinical Care Meeting , Twitter , Dolphin Hotels , Research Clinical Care Meeting In Orlando , Drug Administration , Scholar Rock Inc , Exchange Commission , European Medicines Agency , Linkedin , Johns Hopkins University , Johns Hopkins Medicine , Clinical Care Meeting , Scholar Rock , Chief Executive Officer , Sustained Gains , Motor Function Observed Over , Extended Treatment Period , Hammersmith Functional Motor Scale Expanded , Revised Upper Limb Module , Confidence Interval , Patient Reported Outcomes Consistent , Motor Function , Safety Data , Revised Hammersmith Scale , Fast Track , Orphan Drug , Rare Pediatric Disease , Priority Medicines , Orphan Medicinal Product , Securities Act , Private Securities Litigation Reform Act , Quarterly Report ,